Induction of Donor Specific Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An open-label study to assess the safety, efficacy, and tolerance of FCRx cell therapy in adult recipients within 12 months after kidney transplantation from a living donor.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk

NCT07053462

End-Stage Renal Disease End Stage Renal Disease on Dialysis End Stage Renal Disease With Renal Transplant +4 more

RECRUITING PHASE1/PHASE2

Delayed Infusion of DCreg in Living Donor Liver Transplantation

NCT04208919

Living Donor Liver Transplantation

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Deceased Donor Biomarkers and Recipient Outcomes

NCT01848249

Deceased Donor Kidney Transplant Acute Kidney Injury Delayed Graft Function +2 more

COMPLETED

Technology Enabled And Molecular Monitoring of the Allograft and Transplant rEcipient

NCT05033548

Transplant

TERMINATED

DCreg in Living Donor Liver Transplantation

NCT03164265

Living Donor Liver Transplantation

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Research study which involves the use of a combination of an Enriched Hematopoietic Stem Cell Infusion (stem cells, produced by the bone marrow, generate the cells that form the blood elements, help fight infection and assist in clotting) and kidney transplantation from the same donor to try to avoid the need for long-term anti-rejection drug therapy. The desired result of this study is to allow the body to develop "tolerance" to the transplanted kidney. Tolerance means that the body would see the transplanted kidney as part of the patient and not try to get rid of, or reject it. To prevent rejection, drugs called immunosuppressive agents must be taken on a daily basis. The purpose of this study is to determine if this procedure is safe and to try to substantially reduce or even eliminate the need for anti-rejection medications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Living Kidney Allograft

Recipients with the need for a living kidney allograft are treated with an enriched hematopoietic stem cell infusion from the same living donor

Group Type EXPERIMENTAL

Enriched Hematopoietic Stem Cell Infusion

Intervention Type BIOLOGICAL

Enriched Hematopoietic Stem Cell Infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enriched Hematopoietic Stem Cell Infusion

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must be between the ages of 18 and 65 years and meet the institution's criteria for renal transplantation for end-organ failure
* Meets the transplant criteria by the study site and both the recipient and donor have been accepted as candidates for standard of care living kidney donation and transplantation
* Patient is receiving a renal transplant only
* The crossmatch is negative between donor and recipient. An initial crossmatch will be performed prior to stem cell mobilization to determine if subject can proceed with the apheresis.
* Potential recipients who are women of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours prior to receiving Granulocyte colony-stimulating factor (G-CSF) and agree to use reliable contraception for 1 year following FCRx infusion
* Potential donors who are women of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours prior to receiving G-CSF
* No evidence of donor-specific antibody presently or historically
* Panel Reactive Antibody (PRA) less than or equal to 20

Note: The subjects do not need to be local residents in order to be eligible for this trial, but must be willing to reside in the area, or within a four-hour drive, for the first month of the protocol so that they can be monitored closely in the early post-transplant period.

Exclusion Criteria

* Clinically active bacterial, fungal, viral or parasitic infection
* Pregnancy
* Clinical or serologic evidence of viral infection which would preclude the recipient from receiving a kidney transplant or FCRx infusion
* Previous radiation therapy at a dose which would preclude Total Body Irradiation (TBI)
* Positive crossmatch between donor and recipient
* Evidence for immunologic memory against donor
* Body Mass Index (BMI) \>35 or \<18
* Positive serologies for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), human immunodeficiency virus (HIV)

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No